Skip to main content

Table 1 Clinical baseline data and initial TAVI procedure information

From: Repeat transcatheter aortic valve implantation using a latest generation balloon-expandable device for treatment of failing transcatheter heart valves

  Patient no. 1 Patient no. 2 Patient no. 3
Age (y) 80 78 71
Gender female male male
BMI (kg/m2) 46.6 21 21.6
Comorbidities AF, RI, osteoporosis, s/p TKA both sides, AH, NIDDM AF, 1 VD, prostate cancer, s/p rectum cancer, COPD IV, AH s/p DES in LAD, 3VD, s/p Mitraclip, AF
logEuroSCORE I (%) 23.92 11.89 32.63
logEuroSCORE II (%) 5.54 2.33 19.14
STS PROM (%) 4.69 3.78 2.744
NYHA III III IV
TTE before index procedure    
 LVEF (%) 60 50 30
 EOA (cm2) 0.9 0.7 0.9
 Gradient max/mean (mmHg) 82/41 90/52 30/12
 Valve insufficiency none none none
Index procedure    
 Implanted THV, size (mm) Edwards Sapien XT, 26 JenaValve, 27 CoreValve, 29
 Symptoms after index procedure syncope, dyspnea dyspnea dyspnea
 Time to 2nd procedure (d) 1119 533 814
TTE after index procedure    
 EOA (cm2) / 1.9 2.8
 Gradient max/mean (mm Hg) / 27/10 15/9
 Valve insufficiency mild mild mild
  1. Y years; BMI body mass index; logEuroSCORE logistic European System for Cardiac Operative Risk Evaluation; STS PROM Society of Thoracic Surgeons Predicted Risk of Mortality; NYHA New York Heart Association; TTE transthoracic echocardiography; LVEF left ventricular ejection fraction; EOA effective orifice area; TAVI transcatheter aortic valve implantation; THV transcatheter heart valve; AF atrial fibrillation; RI renal insufficiency; TKA total knee arthroplasty; AH arterial hypertension; NIDDM non insulin dependent diabetes mellitus; VD vessel disease; s/p status post; COPD chronical obstructive pulmonal disease; PVL paravalvular leakage; SD standard deviation